Skip to content
The Nexus
DossierENTITY

VISTA

Coverage of VISTA in the Nexus archive.

Earliest in view: Apr 22 · 11:30 UTCMost recent: Jun 8 · 20:15 UTC
Co-mentioned in this coverage
AstraZenecaorganization1elecogliprontopic1SOLSTICEtopic1obesitytopic1diabetestopic1Ozempictopic1American Diabetes Associationorganization1Lancetorganization1Googleorganization1AItopic1Mountain Viewplace1David Paul Morrisperson1Bloombergorganization1
Recent coverage
  • HEALTHJun 8 · 20:15 UTCSTAT NEWS
    STAT+: AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials

    AstraZeneca's investigational GLP-1 pill, elecoglipron, demonstrated significant weight loss in a Phase 2 obesity trial (11.2% after 36 weeks) and improved blood sugar control in a diabetes trial (1.74 percentage-point A1C reduction). Results were compared to oral Ozempic, which showed a smaller A1C decrease in the same study.

  • TECHNOLOGYApr 22 · 11:30 UTCBLOOMBERG
    Vista Strikes Deal to Speed Up Google AI in Software Portfolio

    Vista has entered a partnership to accelerate the integration of Google's AI technology into its software portfolio. The collaboration aims to enhance performance and capabilities across Vista's software offerings.